The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

AACR 2024 | Can ctDNA guide the treatment decision making process in melanoma?

Name: Can ctDNA guide the treatment decision making process in melanoma?
Uploaded: 2024-04-09T00:00:00Z
Duration: 1 min 20 s

Christoffer Gebhardt • 9 Apr 2024

AACR 2024

Melanoma Skin Cancer

Christoffer Gebhardt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, gives an overview of the emerging role of circulating tumor DNA (ctDNA) in the management of melanoma. Since BRAF mutations occur in approximately half of patients with cutaneous melanoma, ctDNA can have widespread applications, and can assist in patient selection for clinical trials in the adjuvant setting. ctDNA can additionally help clinicians sequence treatments for patients with advanced melanoma. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.